| | PRESS RELEASE Lipid Sciences, Inc. Launches Expanded HDL Therapy Platform in Collaboration With Washington Hospital ... (Site not responding. Last check: 2007-11-07) |
 | | HDL mimetic peptides may serve to stabilize so-called vulnerable plaques, reduce the size of lipid-rich plaques in the arterial wall, and enhance the process of reverse cholesterol transport -- similar to the functionality of HDL treated with Lipid Sciences' proprietary selective delipidation process. |
 | | HDL mimetic peptides can be efficiently and economically synthesized in quantities sufficient for pre-clinical and clinical research, and can be scaled for low-cost, commercial production as a drug. |
 | | The Company's HDL Therapy Platform (selective HDL delipidation and HDL mimetic peptides) is aimed at developing treatments for the reversal of atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. |
| www.marketwire.com /mw/release_html_b1?release_id=93868 (1074 words) |